Thyme Care, a Nashville, TN-based value-based cancer care enabler, raised $95M in Series C funding.
The round was led by Concord Health Partners with participation from all existing investors, including CVS Health Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures, and Foresite Capital. Banc of California will provide an additional $40M in debt financing, bringing Thyme Care’s total amount raised to date to $178M.
The company intends to use the funds to grow and scale the business by expanding into new markets, investing in its existing oncology, primary care, and health plan partnerships, and deepening its clinical value-based care model.
Led by CEO Robin Shah, Thyme Care is a care enabler collaborating with health plans, employers and risk-bearing providers to assume accountability for enhanced care quality, improved health outcomes, and reduced total cost of care. Its approach combines a technology-enabled care team and integration with more than 800 oncologists in Thyme Care Oncology Partners, creating a hybrid collaborative care model that guides and supports the entire patient journey. Its suite of services, including its 24/7 specialized cancer care navigation services, technology and data insights, and provider-led therapeutic interventions enable a patient experience and drive sustainability across the ecosystem. Through its Medicare Advantage and commercial payer agreements, as well as its collaborations in CMS’s Enhancing Oncology Model (EOM), Thyme Care assumes financial responsibility for oncology populations at scale to reduce the total cost of care and improve outcomes and experience.
FinSMEs
16/07/2024